Physician profile
Michael Andrew Springer
NPI 1386639425
$6,669.36
in general payments reported to CMS, 2019-2025
29 companies · $1,093 in 2025
The $1,093 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $458 · 2021: $988 · 2022: $1,266 · 2023: $906 · 2024: $1,259 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,143 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.96 |
| Education | $114.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.32 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $1,030.61 | 2019-2025 | Haegarda, Andembry, Kcentra |
| Genentech USA, INC. | $667.54 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $647.95 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $592.05 | 2019-2025 | Dupixent |
| Genzyme Corporation | $446.36 | 2019-2025 | |
| Kaleo, INC. | $433.27 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $175.65 | 2021-2024 | Orladeyo |
| Amgen INC. | $170.91 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.00 | 2019-2021 | |
| Optinose US, INC. | $157.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $151.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.59 | 2020-2025 | Takhzyro |
| Grifols USA, LLC | $94.68 | 2019-2024 | Prolastin-C Liquid |
| Ars Pharmaceuticals Operations, INC. | $83.63 | 2025 | Neffy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $80.38 | 2025 | Dawnzera |
| Pfizer INC. | $70.54 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $62.60 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.99 | 2025 | |
| Hospira, INC. | $46.69 | 2021 | |
| Alk-Abello, INC | $41.47 | 2021-2022 | |
| Octapharma USA, INC. | $32.75 | 2021-2024 | Cutaquig |
| Abbvie INC. | $24.37 | 2022 | |
| Shire North American Group INC | $21.05 | 2019 | |
| Azurity Pharmaceuticals, INC. | $20.82 | 2025 | Alvesco |
| Pharming Healthcare, INC. | $20.38 | 2025 | Ruconest |
| Hikma Pharmaceuticals USA | $18.91 | 2024 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $15.05 | 2020 | |
| Boston Scientific Corporation | $13.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.